drugset / Trial / NCT00017316

Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma

NCT00017316

Phase 2 Completed 35 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of combining thalidomide and SU5416 in treating patients who have metastatic melanoma. Thalidomide combined with SU5416 may stop the growth of metastatic melanoma by stopping blood flow to the tumor.

Timeline

Start
2001-03
Primary completion
2003-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified Oral
Subject semaxanib Small molecule Intravenous

Indications